• AE
Choose your location?
  • Global Global
  • Australian flag Australia
  • French flag France
  • German flag Germany
  • Irish flag Ireland
  • Italian flag Italy
  • Polish flag Poland
  • Qatar flag Qatar
  • Spanish flag Spain
  • UAE flag UAE
  • UK flag UK

Imogen Francis

Director // Head of Intellectual Property (UK), Birmingham

Imogen delivers tailored, practical advice across the full lifecycle of intellectual property rights, from inception and protection through to enforcement and commercialisation. She works across sectors, with a particular focus on life sciences and technology.
Large image rubine chair

Experience

Imogen is an experienced, personable and responsive lawyer who puts the needs of clients first. She has a broad range of experience, advising on the inception, protection, enforcement and commercialisation of intellectual property across its full lifecycle, including trade marks, copyright, software, patents, designs and domain names.

She works across sectors, but has a particular passion for work in the life sciences and technology sectors. Imogen advises pharmaceutical and biotech clients on their full suite of contracts, including human tissue agreements, MTAs, patent licences, and gives guidance on regulatory-related obligations, such as post authorisation study requirements and MAH obligations. She supports technology clients on high‑value software development and licensing arrangements, open‑source issues and IP commercialisation strategies.

One of her main areas of expertise is in the innovation and research and development space, drawing on her in-house knowledge from secondments with a Russell Group University and an independent life sciences charity. She regularly advises universities, spin-outs and scale ups, on R&D, tech transfer and commercialisation arrangements, particularly relating to new AI products and medical devices.

She also works closely with corporate colleagues on M&As and investments to ensure clients are adequately protected on both acquisition and exit.

Recent experience includes:

  • Advising a University spin-out on its desire to test and exploit a third party’s biomaterials method patent by reviewing and drafting the client's time-sensitive evaluation agreement and complex patent licence.
  • Advising a technology company specialising in misinformation apps on the protection and commercialisation of IPR as part of a wider corporate transaction, including the drafting of precedent documents, including NDAs, a Joint Venture Agreement and an Application Services Agreement between various group companies and proposed customers.
  • Dedicated point of contact for University spin out client operating in the life sciences sector, reviewing various NDAs, MTAs, collaboration and consortium agreements relating largely to the in vitro safety and immunogenicity characterisation of particular vaccines.

Testimonials

  • Software development company: “Imogen recently worked on a tricky IP agreement for us, and she was great! Patient, responsive, pragmatic, and concise – she helped us conclude the matter to our complete satisfaction. A pleasure to work with.”
  • University client: “Imogen is excellent to work with. She demonstrated extensive knowledge in the IP field and is very approachable and friendly which makes dealing with her very pleasant. Her flexible and pragmatic approach to problem solving, responsiveness and ability to provide comprehensive and clear advice makes her an exceptional solicitor.”
  • Global pharmaceutical company: “It’s not only the fact that Imogen’s knowledge was faultless and exactly what was required, but that you can also really relate to her on a human level.”

Memberships

Over the years Imogen has delivered presentations for The Association for Research Managers and Administrators on “BREXIT: Key Project and Contractual Considerations”, the professional development and training provider, MBL Seminars on “An Introduction to Negotiating & Managing R&D Collaboration Agreements” and a group of London spin-out companies on “IPR and Key Contractual Considerations for Spin Outs”.